BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11318895)

  • 1. The utility of cytokeratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma.
    Ormsby AH; Goldblum JR; Rice TW; Richter JE; Gramlich TL
    Histopathology; 2001 Apr; 38(4):307-11. PubMed ID: 11318895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach.
    Ormsby AH; Goldblum JR; Rice TW; Richter JE; Falk GW; Vaezi MF; Gramlich TL
    Hum Pathol; 1999 Mar; 30(3):288-94. PubMed ID: 10088547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
    Shearer C; Going J; Neilson L; Mackay C; Stuart RC
    Histopathology; 2005 Sep; 47(3):268-75. PubMed ID: 16115227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia.
    Mohammed IA; Streutker CJ; Riddell RH
    Mod Pathol; 2002 Jun; 15(6):611-6. PubMed ID: 12065774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology.
    Couvelard A; Cauvin JM; Goldfain D; Rotenberg A; Robaszkiewicz M; Fléjou JF;
    Gut; 2001 Dec; 49(6):761-6. PubMed ID: 11709508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.
    Shen B; Ormsby AH; Shen C; Dumot JA; Shao YW; Bevins CL; Gramlich TL
    Cancer; 2002 Feb; 94(3):820-31. PubMed ID: 11857318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.
    Ormsby AH; Vaezi MF; Richter JE; Goldblum JR; Rice TW; Falk GW; Gramlich TL
    Gastroenterology; 2000 Sep; 119(3):683-90. PubMed ID: 10982762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is cytokeratin immunoreactivity useful in the diagnosis of short-segment Barrett's oesophagus in Korea?
    Yim HJ; Lee SW; Choung RS; Kim YS; Kim JY; Lee HS; Song CW; Choi JH; Bak YT; Ryu HS; Hyun JH; Kim DS; Kim CH
    Eur J Gastroenterol Hepatol; 2005 Jun; 17(6):611-6. PubMed ID: 15879722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified classification for adenocarcinoma of the gastro-oesophageal junction.
    Shearer CJ; Going JJ; Neilson LJ; Stuart RC
    ANZ J Surg; 2007 Jul; 77(7):544-9. PubMed ID: 17610690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction.
    Jovanovic I; Tzardi M; Mouzas IA; Micev M; Pesko P; Milosavljevic T; Zois M; Sganzos M; Delides G; Kanavaros P
    Histol Histopathol; 2002 Apr; 17(2):445-54. PubMed ID: 11962749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus.
    DeMeester SR; Wickramasinghe KS; Lord RV; Friedman A; Balaji NS; Chandrasoma PT; Hagen JA; Peters JH; DeMeester TR
    Am J Gastroenterol; 2002 Oct; 97(10):2514-23. PubMed ID: 12385432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
    Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
    Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia.
    van Lier MG; Bomhof FJ; Leendertse I; Flens M; Balk AT; Loffeld RJ
    J Clin Pathol; 2005 Jul; 58(7):722-4. PubMed ID: 15976339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus.
    Gulmann C; Shaqaqi OA; Grace A; Leader M; Patchett S; Butler D; Kay E
    Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):142-7. PubMed ID: 15354740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach.
    Flucke U; Steinborn E; Dries V; Mönig SP; Schneider PM; Thiele J; Hölscher AH; Dienes HP; Baldus SE
    Histopathology; 2003 Aug; 43(2):127-34. PubMed ID: 12877727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of cytokeratin immunoreactivity pattern for distinction of Barrett's esophagus from intestinal metaplasia of the stomach.
    Iwata T; Kurita N; Nishioka M; Hidenori M; Wakatsuki S; Sano T; Shimada M
    Hepatogastroenterology; 2007 Sep; 54(78):1710-2. PubMed ID: 18019700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
    Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
    Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytokeratin immunoreactivity patterns in the diagnosis of Barrett's esophagus].
    Wang R; Xie J; Shen Y; Ren T
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1820-3. PubMed ID: 23268419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrett's esophagus and intestinal metaplasia of gastric cardia: prevalence, clinical, endoscopic and histological features.
    Pascarenco OD; Boeriu A; Mocan S; Pascarenco G; Drasoveanu S; Galeanu M; Dobru D
    J Gastrointestin Liver Dis; 2014 Mar; 23(1):19-25. PubMed ID: 24689092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratin immunoreactivity patterns in short-segment Barrett's esophagus in Japanese patients.
    Yagi K; Nakamura A; Sekine A
    J Gastroenterol Hepatol; 2005 Jun; 20(6):929-34. PubMed ID: 15946143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.